{
  "query": {
    "country": "US",
    "medicine": "J9271",
    "basis": "part_b_asp"
  },
  "status": "ok",
  "price": {
    "currency": "USD",
    "unit": "per 1 MG",
    "value": 62.253,
    "measure": "average",
    "median": null,
    "typical_low": null,
    "typical_high": null,
    "min": null,
    "max": null
  },
  "sample_size": null,
  "period": {
    "from": "2026-10-01",
    "to": "2026-12-31"
  },
  "confidence": "high",
  "price_type": "reimbursement_price",
  "statistic": {
    "measure": "average",
    "reference_period": "October 2026 quarterly payment limit file",
    "note": "Medicare Part B payment limit (average sales price + 6%): a posted reimbursement rate, not a price paid."
  },
  "as_of": "2026-10-24T11:05:34.674Z",
  "source": {
    "id": "us-cms-asp",
    "name": "Medicare Part B Drug Payment Limit File (ASP pricing files, quarterly)",
    "publisher": "Centers for Medicare & Medicaid Services (CMS), U.S. Department of Health and Human Services",
    "licence": "U.S. Government work, public domain. The CMS ASP Pricing Files page (read 2026-10-23, https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files) shows no licence, copyright or CPT click-through agreement; the same publisher's data is labelled https://www.usa.gov/publicdomain/label/1.0/ on data.gov. Only HCPCS Level II codes and short descriptors are used (CPT descriptors are AMA copyright and are not used).",
    "licence_url": "https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files",
    "attribution": "Source: CMS, Medicare Part B ASP Drug Pricing Files (payment limits). ProofPrice is not affiliated with or endorsed by CMS. Figures are passed on as published; drug names are trademarks of their owners and are used only to name the drug.",
    "url": "https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files"
  },
  "method": "United States (medicines given by a doctor, Medicare Part B): the quarterly Medicare Part B Drug Payment Limit File from CMS. For a drug name or HCPCS code we pass on the published payment limit (the manufacturers' average sales price plus 6%) per billing dosage. A posted Medicare reimbursement rate, not a price paid and not a pharmacy price; the default basis for US medicines is the pharmacy acquisition cost (NADAC).",
  "method_url": "https://proofprice.com/method",
  "summary": "For October 2026, Medicare Part B's payment limit for Inj pembrolizumab (HCPCS J9271) is $62.25 per 1 MG. That is the posted Medicare reimbursement rate (manufacturers' average sales price plus 6%) for drugs given by a doctor, not a price paid and not a pharmacy price. Published by Centers for Medicare & Medicaid Services (CMS), U.S. Department of Health and Human Services for October 2026 quarterly payment limit file.",
  "notice": "Information, not a valuation or offer. Ranges describe past recorded prices.",
  "extra": {
    "what_the_figure_is": "CMS Medicare Part B payment limit per HCPCS billing dosage: average sales price (ASP) + 6%. A reimbursement rate, not a transaction price.",
    "headline_code": "J9271",
    "headline_description": "Inj pembrolizumab",
    "billing_dosage": "1 MG",
    "file": "https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip",
    "other_matches": []
  },
  "answer_id": "ans_f99ce07eb6a5fd0cfa6e",
  "method_version": "1",
  "retrieved_at": "2026-10-24T11:05:34.674Z",
  "evidence": {
    "type": "reimbursement_price",
    "label": "Regulated reimbursement price",
    "meaning": "A price set or reimbursed by a regulator or health system: it is what that scheme pays, not necessarily what a consumer pays in a shop."
  },
  "reliability": "official_median_no_count",
  "data_as_of": "2026-10-24",
  "data_age_days": 0,
  "suggestions": [
    "This is one published figure (an average, median, index or listed price) with no record count: use it as a reference point, not as a range of what individuals paid.",
    "For a decision on a specific job or purchase, ask for an itemised quote."
  ]
}